Interplay between parkin and p53 governs a physiological homeostasis that is disrupted in parkinson's disease and cerebral cancer

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 118-121

  Checler, F ^a   Da Costa, C Alves ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Alzheimer's disease; Cancer; Mutations; p53; Parkin; Parkinson's disease; Transcription factor

Indexed keywords

PARKIN; PROTEIN P53;

ARTICLE; CELL VIABILITY; GENE MUTATION; GLIOMA; HOMEOSTASIS; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; CARCINOGENESIS; CELL DEATH; CELL PROTECTION; CHROMATIN IMMUNOPRECIPITATION; CONFERENCE PAPER; FEEDBACK SYSTEM; GENETIC TRANSCRIPTION; NONHUMAN; SUBSTANTIA NIGRA PARS COMPACTA; TRANSACTIVATION; UPREGULATION;

ANIMALS; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; PARKINSON DISEASE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84896834871     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000354075     Document Type: Article

References (38)

1. Yuan J, Yankner BA: Apoptosis in the nervous system. Nature 2000; 407: 802-809.
2. Evan GI, Vousden K: Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
3. Dawson TM, Dawson VL: Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819-822.
4. Levine AJ, Oren M: The first 30 years of p53: growing ever more complex. Nat Rev 2009; 9: 749-758.
5. Lane DP: Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
6. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP: Awakening guardian angels: drugging the p53 pathway. Nat Rev 2009; 9: 862-873.
7. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12: 25-31.
8. Ruberg M, France-Lanord V, Brugg B, Lambeng N, Michel P, Anglade P, et al: Neuronal death caused by apoptosis in Parkinson disease. Rev Neurol 1997; 153: 499-508.
9. Nair VD: Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis 2006; 11: 955-966.
10. Blum D, Wu Y, Nissou M-F, Arnaud S, Benabid A-L, Verna J-M: p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res 1997; 751: 139-142.
11. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, et al: p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606.
12. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P: p53 mutations in nonastrocytic human brain tumors. Cancer Res 1991; 51: 6202-6205.
13. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, et al: p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004; 52: 228-232.
14. Royds JA, Iacopetta B: p53 and disease: when the guardian angel fails. Cell Death Differ 2006; 13: 1017-1026.
15. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302-305.
16. Corti O, Lesage S, Brice A: What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011; 91: 1161-1218.
17. da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A, et al: Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11: 1370-1375.
18. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, et al: Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci USA 2011; 108: 16259-16264.
19. Viotti J, Duplan E, Caillava C, Condat J, Goiran T, Giordano C, et al: Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Oncogene 2013, E-pub ahead of print.
20. Cookson MR, Lockhart PJ, McLendon C, O'Farrell C, Schlossmacher M, Farrer MJ: RING finger 1 mutations in Parkin produce altered localization of the protein. Hum Mol Genet 2003; 12: 2957-2965.
21. Horowitz JM, Myers J, Vernace VA, Stachowiak MK, Torres G: Spatial distribution, cellular integration and stage development of Parkin protein in Xenopus brain. Brain Res Dev Brain Res 2001; 126: 31-41.
22. Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, Kast J, et al: Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 2011; 18: 769-782.
23. Cali T, Ottolini D, Negro A, Brini M: Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics. Biochim Biophys Acta 2013; 1832: 495-508.
24. Duplan E, Giaime E, Viotti J, Sevalle J, Corti O, Brice A, et al: ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1. J Cell Sci 2013; 126: 2124-2133.
25. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al: Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000; 342: 1560-1567.
26. Martin I, Dawson VL, Dawson TM: Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet 2011; 12: 301-325.
27. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, et al: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3: 523-530.
28. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, et al: Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro Oncol 1999; 1: 124-137.
29. Alves da Costa C, Paitel E, Mattson MP, Amson R, Telerman A, Ancolio K, et al: Wildtype and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc Natl Acad Sci USA 2002; 99: 4043-4048.
30. Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Boyer N, et al: Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 2006; 26: 6377-6385.
31. Dunys J, Kawarai T, Sevalle J, Dolcini V, George-Hyslop PS, Da Costa CA, et al: p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity. J Biol Chem 2007; 282: 10516-10525.
32. Dunys J, Sevalle J, Giaime E, Pardossi-Piquard R, Vitek MP, Renbaum P, et al: p53-dependent control of transactivation of the Pen2 promoter by presenilins. J Cell Sci 2009; 122: 4003-4008.
33. Checler F, Dunys J, Pardossi-Piquard R, Alves da Costa C: p53 is regulated by and regulates members of the gamma-secretase complex. Neurodegener Dis 2010; 7: 50-55.
34. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185.
35. Burns MP, Zhang L, Rebeck GW, Querfurth HW, Moussa CE: Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet 2009; 18: 3206-3216.
36. Rosen KM, Moussa CE, Lee HK, Kumar P, Kitada T, Qin G, et al: Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. J Neurosci Res 2010; 88: 167-178.
37. Wolfe MS, Haass C: The role of presenilins in gamma-secretase activity. J Biol Chem 2001; 276: 5413-5416.
38. Duplan E, Sevalle J, Viotti J, Goiran T, Bauer C, Renbaum P, et al: Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. J Mol Cell Biol 2013; 5: 132-142.